Goldenwell Biotech (GWLL) faces going‑concern after losses, related‑party and disclosure issues

Goldenwell Biotech, Inc. (PINK: GWLL)

Straight to the point: the company is an early‑stage nutraceutical/supplements developer with minimal product sales, recurring operating losses, reliance on related‑party financing, and multiple disclosure inconsistencies across the filing. Management warns of substantial doubt about the company's ability to continue as a going concern.

Key points & statistics (reported)

- Cash (June 30, 2025): $76,507
- Inventory (related‑party): $174,788
- Total assets: $251,295
- Total liabilities (Balance Sheet): $338,133
- Stockholders' equity (deficit): $(86,838)
- Net loss (three months ended 6/30/2025): $(5,220)
- Net loss (six months ended 6/30/2025): $(39,596)
- Weighted average shares outstanding: 96,433,333
- Accumulated net loss since inception: $1,399,241 (going‑concern note)
- Related‑party loans reported: $95,588 on the balance sheet (Note text references $95,599)
- Statement of operations shows sales of $139 (3 months) and $297 (6 months); service revenue is shown in the filing (statement) as $37,500 (presentation in the filing is inconsistent with MD&A)
- Net cash used in operating activities (three months): $59,380; (six months): $27,104
- Management estimates ~$5,000,000 needed to construct manufacturing and scale operations (MD&A)

Positive items

- Cash increased to $76.5k at June 30, 2025 (up from $49,404 at Dec 31, 2024).
- Company has recorded some revenue (sales and service income) instead of zero sales - early commercial activity exists.
- No pending legal proceedings reported. Management is transparent about going‑concern risk and related‑party transactions.

Negative / risks (income statement and broader)

- Recurring losses: net loss of $39,596 for the six months - the company remains unprofitable and has an accumulated deficit of $1.399M.
- Operating expenses (G&A) remain material relative to tiny revenues (G&A: $40,620 for the quarter; $72,896 for six months).
- Gross profit is driven by a small amount of service revenue; product sales are negligible ($139 for the quarter). Business is not yet economically viable.
- Cash flows: negative operating cash flow ($59,380 used in the quarter). The company depends on financing to continue operations and has not generated sustainable cash from operations.
- Related‑party exposure: material inventory purchase from a company owned by the treasurer and multiple loans from the CEO - increases governance and conflict risk.
- Balance sheet weakness: liabilities exceed assets and stockholders' equity is negative - substantial doubt about ability to continue as a going concern (company states this explicitly).
- Disclosure inconsistencies: several numbers differ between the financial statements and MD&A/notes (e.g., service revenue, working capital, total liabilities, related‑party loan amount), which raises reporting reliability concerns.

What to watch next

- Any capital raise (equity or third‑party debt) - the company says it needs substantial funding (~$5.0M) to build manufacturing and scale.
- Clarifications in future filings to resolve the inconsistencies (revenue, working capital, liabilities, and related‑party loan balances).
- Progress on converting inventory into repeatable product sales and any reduction in operating cash burn.

Bottom line: Goldenwell Biotech (PINK: GWLL) is a very early‑stage, cash‑constrained micro‑cap with modest revenue activity but continued losses, negative equity, and reliance on related‑party funding. Investors should require clearer, consistent reporting and a credible financing plan before considering exposure.